



Rajani™ (drospirenone/ethinyl estradiol/levomefolate and levomefolate) – First-Time Generic

- On October 12, 2016, [Teva announced](#) the launch of [Rajani \(drospirenone/ethinyl estradiol \[EE\]/levomefolate calcium and levomefolate calcium\)](#) tablets, a generic equivalent of Bayer's [Beyaz \(drospirenone/EE/levomefolate calcium and levomefolate calcium\)](#) tablets.
- Rajani is an estrogen/progestin combined oral contraceptive containing a folate, indicated for use by women for:
 - Prevention of pregnancy
 - Treatment of symptoms of premenstrual dysphoric disorder in women who choose to use an oral contraceptive for contraception
 - Treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche
 - Women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product
- Beyaz had annual sales of approximately \$133 million in the U.S., according to IMS data as of July 2016.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.